EGFR mutation based on lung laterality in adenocarcinoma type of non-small cell lung cancer
Abstract
Targeted therapies have shown promise in improving survival rates for lung adenocarcinoma, a common and deadly malignancy. EGFR-targeting tyrosine kinase inhibitors (TKIs) are particularly effective among these therapies in cases with EGFR mutations. Detecting these mutations before TKI treatment is essential. Various radiological features have been linked to EGFR mutations. However, the relationship between tumor location and mutation types in Indonesian lung adenocarcinoma patients remains unexplored. This study aimed to identify the frequency of EGFR mutation in local lung adenocarcinoma cases based on the tumor location. Clinical data of lung adenocarcinoma patients (n = 272) diagnosed between 2018 and 2022 were retrospectively taken from the Department of Anatomical Pathology, Dr. Sardjito General Hospital, Yogyakarta. The qRT-PCR data of EGFR mutation status was obtained from the Department of Anatomical Pathology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta. Descriptive analysis was performed using STATA version 14.0. EGFR mutations were found in 60.7% of patients, with 58.2% having exon 19 mutations and 21.2% exhibiting exon 21 L858R mutations. Mutation status was found to be significantly different based on the patient's gender (p = 0.022) and age (p = 0.029) but not with lung laterality (p = 0.093). The proportion of exon 19, exon 21 L858R, and uncommon mutations in the right and left lung adenocarcinoma was similar across all samples. This study found no difference between specific EGFR mutation types and tumor location in lung adenocarcinoma.
References
Borczuk AC. WHO classification of tumours: thoracic tumours. International Agency for Research on Cancer; 2021.
Sharma R. Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050. Int J Clin Oncol 2022; 27(4):665-75.
https://doi.org/10.1007/s10147-021-02108-2
Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer 2024.
https://gco.iarc.who.int/media/globocan/factsheets/populations/360-indonesia-fact-sheet.pdf
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3):209-49.
https://doi.org/10.3322/caac.21660
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391(10125):1023-75.
https://doi.org/10.1016/S0140-6736(17)33326-3
Brainard J, Farver C. The diagnosis of non-small cell lung cancer in the molecular era. Mod Pathol 2019; 32(Suppl 1):16-26.
https://doi.org/10.1038/s41379-018-0156-x
Socinski MA, Evans T, Gettinger S, Hensing TA, Sequist LV, Ireland B, et al. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(5):e341S-68S.
https://doi.org/10.1378/chest.12-2361
Harsal A, Suratman E, Tambunan T. P1-038: Overview of lung cancer in Dharmais National Cancer Hospital, Jakarta, Indonesia. J Thor Oncol 2007; 2(8):S564.
https://doi.org/10.1097/01.JTO.0000283652.11456.81
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2022; 20(5):497-530.
https://doi.org/10.6004/jnccn.2022.0025
Malapelle U, Pilotto S, Passiglia F, Pepe F, Pisapia P, Righi L, et al. Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. Crit Rev Oncol Hematol 2021; 160:103300.
https://doi.org/10.1016/j.critrevonc.2021.103300
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsuratani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11(2):121-8.
https://doi.org/10.1016/S1470-2045(09)70364-X
Gristina V, Malapelle U, Galvano A, Pisapia P, Pepe F, Rolfo C, et al. The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. Cancer Treat Rev 2020; 85:101994.
https://doi.org/10.1016/j.ctrv.2020.101994
Jorge SEDC, Kobayashi SS, Costa DB. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz J Med Biol Res 2014; 47(11):929-39.
https://doi.org/10.1590/1414-431X20144099
Tseng CH, Chen KC, Hsu KH, Tseng JS, Ho CC, Hsia TC, et al. EGFR mutation and lobar location of lung adenocarcinoma. Carcinogenesis 2016; 37(2):157-62.
https://doi.org/10.1093/carcin/bgv168
Shi Z, Zheng X, Shi R, Song S, Yang R, Zhang Q, et al. Radiological and clinical features associated with epidermal growth factor receptor mutation status of exon 19 and 21 in lung adenocarcinoma. Sci Rep 2017; 7(1):364.
https://doi.org/10.1038/s41598-017-00511-2
Lamberti G, Andrini E, Sisi M, Rizzo A, Parisi C, Federico AD, et al. Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. Crit Rev Oncol Hematol 2020; 156:103119.
https://doi.org/10.1016/j.critrevonc.2020.103119
Mulawarman A, Haryana SM, Sadewa AH. Ekspresi Serum miR-148 dan miR-155 sebagai kandidat biomarker prognosis kanker paru jenis karsinoma bukan sel kecil (KPKBSK) stage lanjut di Indonesia menggunakan liquid biopsy [Dissertation]. Yogyakarta: Universitas Gadjah Mada; 2020.
Melosky B, Kambartel K, Haentschel M, Bennetts M, Nickens DJ, Brinkmann J, et al. Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis. Mol Diagn Ther 2022; 26(1):7-18.
https://doi.org/10.1007/s40291-021-00563-1
Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health 2019; 85(1):8.
https://doi.org/10.5334/aogh.2419
Nakamura H, Saji H. A worldwide trend of increasing primary adenocarcinoma of the lung. Surg Today 2014; 44(6):1004-12.
https://doi.org/10.1007/s00595-013-0636-z
Zhou L, Li H, Yang S. Age does matter in adolescents and young adults vs. older adults with lung adenocarcinoma: A retrospective analysis comparing clinical characteristics and outcomes in response to systematic treatments. Oncol Lett 2022; 24(4):362.
https://doi.org/10.3892/ol.2022.13482
Ueno T, Toyooka S, Suda K, Soh J, Yatabe Y, Miyoshi S, et al. Impact of age on epidermal growth factor receptor mutation in lung cancer. Lung Cancer 2012; 78(3):207-11.
https://doi.org/10.1016/j.lungcan.2012.09.006
Arslan SA, Aral İP, Altınışık İnan G, Karabuga H, Acikgoz S, Unal I, et al. Right predilection of lung cancer, does it affect oncologic outcome?. Acta Oncol Turc 2019; 52(2):232-7.
https://doi.org/10.5505/aot.2019.01488
Liu G, Xu Z, Ge Y, Jiang B, Groen H, Vliegenthart R, et al. 3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma. Transl Lung Cancer Res 2020; 9(4):1212-24.
https://doi.org/10.21037/tlcr-20-122
Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 2015; 5(9):2892-911.
Quan X, Gao H, Wang Z, Li J, Zhao W, Liang W, et al. Epidermal growth factor receptor somatic mutation analysis in 354 Chinese patients with non-small cell lung cancer. Oncol Lett 2018; 15(2):2131-8.
https://doi.org/10.3892/ol.2017.7622
Syahruddin E, Wulandari L, Sri Muktiati N, Rima A, Soeroso N, Ermayanti S, et al. Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients. Lung Cancer (Auckl) 2018; 9:25-34.
https://doi.org/10.2147/LCTT.S154116
Imyanitov EN, Demidova IA, Gordiev MG, Filipenko ML, Kekeyeva TV, Moliaka YK, et al. Distribution of EGFR mutations in 10,607 Russian patients with lung cancer. Mol Diagn Ther 2016; 20(4):401-6.
https://doi.org/10.1007/s40291-016-0213-4
Tanaka K, Shimizu K, Kakegawa S, Ohtaki Y, Nagasima T, Kaira K, et al. Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma. Am J Transl Res 2016; 8(1):81-97.
Herceg Z, Hainaut P. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Mol Oncol 2007; 1(1):26-41.
https://doi.org/10.1016/j.molonc.2007.01.004
Hsu CL, Chen KY, Shih JY, Ho CC, Yang CH, Yu CJ, et al. Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors. BMC Cancer 2012; 12:241.
https://doi.org/10.1186/1471-2407-12-241
Rizzo S, Petrella F, Buscarino V, De Maria F, Raimondi S, Barberis M, et al. CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur Radiol 2016; 26(1):32-42.
https://doi.org/10.1007/s00330-015-3814-0
Isaka T, Yokose T, Ito H, Nagata M, Furumoto H, Nishii T, et al. Correlations between the EGFR mutation status and clinicopathological features of clinical stage I lung adenocarcinoma. Medicine (Baltimore) 2015; 94(42):e1784.
